Results

Twenty-eight patients (76±11 years) were included. The median baseline PSA was 29[14-89] ng/ml.

The mean time to achieve this reduction was 13±15 weeks.

PSA-RR at week 12 was 31% (9 patients).

Median bPFS

Patients with a baseline PSA declined after starting KT (n=23): 87[IC95%: 35-139] weeks.
Patients with a ≥ 50% PSA decline at 12 weeks: median bPFS not reached at the time of data analysis.

Conclusions

• Approximately one third of patients treated with KT experienced rapid PSA declines close to those observed with abiraterone (37-42%).
• The PSA-RR, the significant bPFS, its low cost and the possibility of starting abiraterone after KT highlight KT as an alternative in chemo-naïve patients with mCRPC.